ArticleAmerican journal of cancer research2022

Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

Wei Teng et al.PubMed ↗Full text ↗

No numbers read from the abstract.